First-line Sunitinib and Pazopanib Are Similarly Effective on mRCC

Share this content:
Sunitinib and pazopanib may be similarly effective for the first-line treatment of metastatic renal cell carcinoma.
Sunitinib and pazopanib may be similarly effective for the first-line treatment of metastatic renal cell carcinoma.

Sunitinib and pazopanib may be similarly effective for the first-line treatment of metastatic renal cell carcinoma (mRCC), and do not affect outcomes with second-line systemic therapy, according to a “real-world” study published in the European Journal of Cancer.1

Both sunitinib and pazopanib are approved by the U.S. Food and Drug Administration for the first-line treatment of mRCC, though it is unclear how the clinical efficacy of these agents translates into “real-world” effectiveness. Researchers compared outcomes with each agent using population-based data.

Investigators analyzed data from 7483 patients with mRCC treated with either frontline sunitinib or pazopanib who were included in the International mRCC Database Consortium (IMDC). There were no significant differences in IMDC prognostic groups (P = .36).

After a median follow-up of 40.4 months (95% CI, 39.2-42.1), there was no significant difference in median overall survival between the 2 groups (22.3 months for sunitinib versus 22.6 months for pazopanib; P = .65).

Median progression-free survival was 8.4 months with sunitinib, compared with 8.3 months with pazopanib (P = .17).

After adjusting for IMDC criteria, researchers found that there was no significant difference in the risk of death for pazopanib versus sunitinib (hazard ratio, 1.03; 95% CI, 0.92-1.17; P = .58). There was also no difference in the risk of disease progression (hazard ratio, 1.08; 95% CI, 0.981-1.19; P = .12).

RELATED: Biomarkers May Identify Which Patients With Renal Cell Carcinoma Will Benefit From Nivolumab

No differences were found in overall survival (P = .27) or progression-free survival (P = .07) after second-line treatment between the post-sunitinib and post-pazopanib groups.                            

Reference

  1. Ruiz-Morales JM, Swierkowski M, Wells JC, et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur J Cancer. 2016;65:102-108.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters